Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab short-duration infusion in previously untreated advanced follicular lymphoma
NL-OMON49850Phase 4Completed
- Sponsor
- Roche
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of obinutuzumab in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by Roche. Primary endpoint: Incidence of Grade 3 or higher infusion-related reactions during the first short-duration infusion cycle. Started Jul 2019; status: completed.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON49850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49850.